Integrated Biopharma, Inc.
INBP
$0.32
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -10.48% | 1.63% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -10.48% | 1.63% | |||
| Cost of Revenue | -8.15% | 2.50% | |||
| Gross Profit | -30.63% | -5.29% | |||
| SG&A Expenses | -2.73% | 8.37% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.80% | 2.86% | |||
| Operating Income | -72.33% | -20.30% | |||
| Income Before Tax | -67.06% | -23.52% | |||
| Income Tax Expenses | -90.56% | 362.87% | |||
| Earnings from Continuing Operations | 169.10% | -129.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 169.10% | -129.13% | |||
| EBIT | -72.33% | -20.30% | |||
| EBITDA | -63.64% | -19.02% | |||
| EPS Basic | 168.97% | -128.71% | |||
| Normalized Basic EPS | -68.29% | -19.61% | |||
| EPS Diluted | 167.24% | -129.00% | |||
| Normalized Diluted EPS | -68.29% | -16.89% | |||
| Average Basic Shares Outstanding | 1.47% | 1.02% | |||
| Average Diluted Shares Outstanding | 2.65% | -2.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||